# ASIAN JOURNAL OF PHARMACEUTICAL AND BIOLOGICAL RESEARCH





Asian journal of Pharmaceutical and biological research 2231-2218 http://www.ajpbr.org/ Universal IMPACT factor 7 SJIF 2022: 4.465 Volume 12 Issue 2 **MAY-AUG. 2023 Editorial board** Dr. Madhu Bala Scientist 'F' and Joint Director, Institute of Nuclear Medicine and Allied Sciences (INMAS), India Dr. Sandip Narayan Chakraborty Research Asst, Translational Molecular Pathology, Ut Md Anderson Cancer Center, Life Sciences Plaza, Houston, TX 77030 Dr. Tushar Treembak Shelke Head of Department of Pharmacology and Research Scholar, In Jspms Charak College of Pharmacy & Research, Pune, India Dr. Subas Chandra Dinda Professor-cum-Director: School of Pharmaceutical Education & Research (SPER), Berhampur University, Berhampur, Orissa, India. Dr. Jagdale Swati Changdeo Professor and Head, Department of Pharmaceutics, MAEER's Maharashtra Institute of Pharmacy, S.No.124, MIT Campus, Kothrud, Pune-411038 Dr. Biplab Kumar Dey Principal, Department of Pharmacy, Assam downtown University, Sankar Madhab Path, Panikhaiti 781026, Guwahati, Assam, India Dr. Yogesh Pandurang Talekar Research Associate, National Toxicology Centre Dr. Indranil Chanda Assistant Professor, Girijananda Chowdhury Institute of Pharmaceutical Science, Hathkhowapara, Azara Guwahati-17, Assam, India. Dr. Sudip Kumar Mandal Department of Pharmaceutical Chemistry, Dr. B. C. Roy College of Pharmacy & AHS, Bidhannagar, Durgapur-713206, India. Sodikova Dilrabokhon Andijan state medical institute Dr., associate professor Kuryazova Sharofat Tashkent Pediatric medical institute Dr., Abdurakhmanova Nigora Nazimovna Tashkent Pediatric Medical Institute Abdullaeva Umida Bukhara state medical institute Dr. Neeraj Upmanyu Prof., Peoples Institute of Pharmacy & Research Center, Bhopal, MP, India. Dr. Mirrakhimova Maktuba Khabibullaevna Tashkent medical academy Uzbekistan Dr. Nishanova Aziza Abdurashidovna, Tashkent State Dental Institute Dr. Sadikova Minurakhon Adkhamovna Andijan State Medical Institute Kurbanova Sanobar Yuldashevna Tashkent State Dental Institute Zokirova Nargiza Bahodirovna Tashkent Pediatric medical institute Khabilov Behzod Nigmon ugli Tashkent State Dental Institute Dr. Domenico De Berardis Department of Mental Health, Azienda Sanitaria Locale Teramo, 64100 Teramo. Italy Dr. Azizova Rano Baxodirovna associate professor of the Department of neurology of the Tashkent Medical Academy Dr. Ishankhodjaeva Gulchekhra Tashkent Medical Academy

Institute of Nuclear Medicine and Allied Sciences (INMAS), India

Brig SK Mazumdar Marg, Timarpur, New Delhi, Delhi 110054 India

Asian journal of Pharmaceutical and biological research <u>2231-2218</u> <u>http://www.ajpbr.org/</u> <u>Universal IMPACT factor 7</u> <u>SJIF 2022: 4.465</u> Volume 12 Issue 2 MAY-AUG, 2023

### NEPHROTIC SYNDROME MANIFESTATION IN THE POST-COVID PERIOD (Clinical case) Safarova Gulnoz Avazkhanovna

Bukhara State Medical Institute.

Department of Faculty and Hospital Therapy, Nephrology and Hemodialysis,

assistant

**Relevance.** Coronavirus infection is hazardous not only because of inflammation and lung tissue damage[1]. Complications of the condition, in any form, affect the heart, brain, and kidneys. 59% of all problems involve the urinary system[2]. Protein has been identified in the urine of patients in the provinces of Sichuan and Hubei, and blood is found in nearly one in every two.

Acute renal damage is one of the reasons in covid death in severe instances, hence screening should begin as soon as feasible. Sluggish and latent urinary system abnormalities emerge quickly in certain patients with coronavirus disease[3,4].

Target. To describe the characteristics of cryoglobulinemic nephropathy in the post-COVID phase.

Keywords: Nephropathy, post-COVID period, glomerulonephritis.

**Material and methods.** Patient K, 61, was hospitalized to the Bukhara Regional Multidisciplinary Medical Center's therapeutic department with symptoms of lumbar discomfort, belly enlargement, and shortness of breath after activity. According to the anamnesis, she had viral hepatitis C eight years ago. She contracted a fresh coronavirus infection in March 2022.

On arrival, the patient was in a moderately severe state with ascites and pastosity of the legs and feet. Laboratory research methods: platelets 63·109/l; C-reactive protein 24.3 mg/l; total protein 46g/l; total bilirubin 9.4 µmol/l; ALT 26 U/l; AST 20 U/l; ALP 68 U/l; urea 11.3 mmol/l; creatinine 139 µmol/l; uric acid 0.6 mmol/l; potassium 5.8 mmol/l; sodium 125 mmol/l; APTT 24 sec.; prothrombin according to Quick 101.2%; INR 1.04; Anti-HCV total - detected; HCV RNA was not detected quantitatively. Urinalysis: quantitative protein 1.578 g/l; leukocytes 9.45 cells/p. sp.; erythrocytes 658.6 cells/p. sp.; Urinalysis according to Nechiporenko: leukocytes 20·106/l; erythrocytes 1250·106/l. According to ultrasound data, free fluid in the pleural cavities on both sides is free fluid, diffuse changes in the liver like cirrhosis, portal hypertension, splenomegaly, ascites. Diffuse changes - glands, kidneys. Elastometry of the liver, the degree of fibrosis according to the METAVIR F1 scale[5,6].(1-3 tables)

**Results.** As a result of the differential diagnosis search, nephrotic syndrome was confirmed within the context of "Cryoglobulinemic glomerulonephritis," one of the secondary types of kidney injury.

Asian journal of Pharmaceutical and biological research <u>2231-2218</u> <u>http://www.ajpbr.org/</u> <u>Universal IMPACT factor 7</u> <u>SJIF 2022: 4.465</u> Volume 12 Issue 2 MAY-AUG. 2023

**Conclusion.** In light of the preceding, it is of significant clinical and scientific interest to investigate the potential effects of a novel coronavirus infection COVID-19 in extrapulmonary localizations, including kidney injury.

#### Table-1

# Экспресс-диагностика для качественного и количественного гепатитов

Ф.И.О	Год.рождение		Дата <mark>7.06.2022</mark>	
Наименование	Результат.	Результат.	Норма	Норма
HbsAg	Отрицательный	0,122	Отрицательный	0,126
(гепатит В)				
Anti HCV	Положительный	1,786	Отрицательный	0,142
(гепатит С)				

## Table-2

# ОБЩИЙ АНАЛИЗ МОЧИ.

	Физическое-химическое свойства			
N	Показатель	Результат	Норма	
1	Количество	60 мл	50-100мл	
2	Цвет	Солом, жёлтый	Солом, жёлтый	
3	Прозрачность	Прозрачный	Прозрачный	
4	Лейкоциты	9,45	- шт/мкл	
7	Белок	1,578	До 0,15 г/л	
9	Реакция Ph	6.0	5,0 - 6.0	
10	Кровь	658,6	- шт/мкл	

#### Анализ мочи по Нечипоренко

.N⊵	Исследуемый показатель	-	Результаты исследования
1	Количество лейкоцитов	До 4000 в 1 мл	20
2	Количество эритроцитов	До 1000 в 1 мл	1250
3	Количество цилиндров	отсутствуют	-

# Table-3

Asian journal of Pharmaceutical and biological research <u>2231-2218</u> <u>http://www.ajpbr.org/</u> <u>Universal IMPACT factor 7</u> <u>SJIF 2022: 4.465</u> Volume 12 Issue 2 MAY-AUG. 2023

141		
	Ф.И.О	
	Φ.Μ.Ο	
	Дата рождения	
	Дата	
	<b>T</b>	

# Биохимическое исследование крови

N≘	Наименование		
	нсследовання	РЕЗУЛЬТАТ	HOPMA
1	АЛТ (аланинаминотрансфераза)	26	Мужчины: до 40 U/L.
			Женщины: до 31 U/L
2	АСТ (аспартатаминотрансфераза)	20	Мужчины: до 37 U/L.
			Женщины: до 31 U/L
3	Билирубин общий	9,4	до-19 мкмоль/п
4	Билирубин прямой	4	до >5,1 мямодь/л
- 5	Билирубин непрямой	5.4	до >15,4 <u>мямоль</u> /л
6	Глюкоза	6.4	4,2-6,4 <u>ммоль</u> /п
7	Мочевина	11,8	1,7-8,3 ммоль/л
8	Креатинин	139	Мужчины: 62 - 124 мкмоль/л.
			Женщины: 53 – 97 <u>ықыодь</u> /л
10	Мочевая кислота	0,6	Мужчины: 200-416 мкмоль/л.
			Женщины: 142-339 <u>ықыодь</u> /л
11	Альбумин		38-44 г/л
12	Общий белок	46	до 3 лет: 46-70 г/л
			от 3 лет и взрослые: 66-87г/л
13	Альфа-амилаза		до >120 МЕ/Л
14	Щелочная фосфатаза	68	26-117 МЕ/п
15	Гамма - глутаминтрансфераза		Мужчины: до >50 Ед/л
			Женщины: до >32 <u>Ед</u> /л
16	Кальций		2.15-2.55 ммоль/л
17	Калий	5,8	3.5-5.6 ммоль/л
18	Железа (Fe**)		10.6-28.3 ммоль/л
19	Натрий	125	

### Literature:

1. Safarova G.A. Features of the clinical course of covid-19 in comorbid conditions (A literature review) //New day in medicine 6 (38) 2021 ISSN 2181-712X. EISSN 2181-2187 pages 88-95

2. Safarova G.A. Indicators of kidney damage in type II diabetes mellitus in preclinical stages. // Infection, immunity and pharmacology №6/2021 ISSN 2181-5534 Pages 162-167

Asian journal of Pharmaceutical and biological research <u>2231-2218</u> <u>http://www.ajpbr.org/</u> <u>Universal IMPACT factor 7</u> <u>SJIF 2022: 4.465</u> Volume 12 Issue 2 MAY-AUG. 2023

3. Safarova G.A. Vasorenal hemodynamic changes in patients with chronic kidney disease in comorbidity with hypertonic disease. Asian journal of Pharmaceutical and biological research 2231-2218 http://www.ajpbr.org/ Volume 10. Issue 2. MAY-AUG 2021 10.5281/zenodo.5464135 Page 66-71

4. Safarova G.A., Mukhamedjanova M.Kh. Early dopplerographic diagnostics of nephropathy in patients with essential arterial hypertension. // Problems of biology and medicine 2021, №6 (132) Pages 107-111

5. Mukhamedjanova MH Anemia in patients with interferences and interpretation of modern therapy. NDM 4(36)2021 P150-152

6. Mukhamedzhanova M. Kh., Ahmedova N.Sh.. Determination of hepsidin in patients with chronic hepatitis associated with chf as a predictor of the severity of hepatocardial syndrome.// Art of Medicine International Medical Scientific Journal 10.5281/zenodo.7361300 Vol 2, Issue 3 P.332-336